Novo Nordisk A/S (NYSE:NVO) to Issue $0.58 Dividend

Novo Nordisk A/S (NYSE:NVO) declared a dividend on Wednesday, August 5th. Stockholders of record on Monday, August 17th will be given a dividend of 0.5786 per share on Tuesday, August 25th. This represents a dividend yield of 254.0%. The ex-dividend date of this dividend is Monday, August 17th.

Novo Nordisk A/S has increased its dividend by an average of 0.2%annually over the last three years. Novo Nordisk A/S has a payout ratio of 36.9% meaning its dividend is sufficiently covered by earnings. Research analysts expect Novo Nordisk A/S to earn $3.28 per share next year, which means the company should continue to be able to cover its $1.74 annual dividend with an expected future payout ratio of 53.0%.

Novo Nordisk A/S Stock Performance

NVO stock traded up $1.12 during trading on Thursday, reaching $45.65. The stock had a trading volume of 7,682,218 shares, compared to its average volume of 18,238,273. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $64.16. The firm has a market cap of $203.81 billion, a PE ratio of 11.16, a PEG ratio of 4.03 and a beta of 0.76. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The stock’s 50 day moving average is $46.96 and its two-hundred day moving average is $45.12.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The firm had revenue of $11.98 billion during the quarter. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.39 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.